



1PW

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants: Junming Le, Jan Vilcek, Peter Daddona, John Ghrayeb, David Knight and
Scott Siegel

Application No.: 10/665,971 Group: 1642

Filed: September 19, 2003 Examiner: Karen A. Canella

Confirmation No.: 5342

For: METHODS OF TREATING NEURODEGENERATIVE INFLAMMATION
WITH CHIMERIC ANTI-TNF ANTIBODIES

CERTIFICATE OF MAILING OR TRANSMISSION	
I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as First Class Mail in an envelope addressed to Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, or is being facsimile transmitted to the United States Patent and Trademark Office on:	
3-4-05	<i>Jane Morgan</i>
Date	Signature
JANE MORGAN	
Typed or printed name of person signing certificate	

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

This Information Disclosure Statement is submitted under 37 CFR 1.97(b) before the mailing date of a first office action on the merits in the above-referenced application.

INFORMATION FROM RELATED LITIGATION

The Rockefeller University and Chiron Corporation have filed a complaint in The United States District Court For The Eastern District of Texas, Marshall Division, Civil Action No. 2-04CV-16, against Centocor, Inc., an assignee of this application, for infringement of U.S. Patent Nos: 6,309,640 and 6,419,927. The accused infringement relates to Centocor, Inc.'s product, REMICADE® infliximab. REMICADE® infliximab is also known as cA2, which is recited in the claims and specification in this application. The validity of this patent application is not at issue in the litigation. Nor is the validity of any related patents or patent applications at issue in this litigation.

Enclosed herewith is Form PTO-1449, citing U.S. Patent Nos: 6,309,640 and 6,419,927 and their related European application. Copies of these cited references (AC3, AD3 and AP7, respectively) are enclosed.

Applicants do not believe that this information is relevant or material to patentability. Applicants merely cite this information in an abundance of caution. Further, Applicants believe that this information is cumulative to References AA and AB, which were cited in the Information Disclosure Statement filed in this application on May 25, 2004. Reference AC3 is a continuation application of Reference AD3, which is, in turn, a continuation application of References AA and AB and thus have substantially identical disclosures and have the same priority date. In addition, Reference AP7 claims priority to the same priority applications as References AA and AB and has a substantially identical disclosure.

Applicants request that the information disclosed herein be made of record in this application. Applicants respectfully request that the Examiner return a copy of this Supplemental Information Disclosure Statement and acknowledge the information from the related litigation.

Examiner

Date

Method of payment:

- [] A check for the fee noted above is enclosed, or the fee has been included in the check with the accompanying Reply. A copy of this Statement is enclosed.
- [X] Please charge any deficiency in fees and credit any overpayment to Deposit Account 08-0380.

Respectfully submitted,

HAMILTON, BROOK, SMITH & REYNOLDS, P.C.

By Deirdre E. Sanders

Deirdre E. Sanders
Registration No.: 42,122
Telephone: (978) 341-0036
Facsimile: (978) 341-0136

Concord, MA 01742-9133

Dated: March 4, 2005

APPLICATION NO.
10/665,971

FIRST NAMED INVENTOR
Junming Le

FILING DATE
September 19, 2003

March 4, 2005

EXAMINER
Karen A. Canella

CONFIRMATION NO.
5342

GROUP
1642

(Use several sheets if necessary)

U.S. PATENT DOCUMENTS

[illegible]

EXAMINER

DATE CONSIDERED

March 4, 2005

(Use several sheets if necessary)

FILING DATE
September 19, 2003

CONFIRMATION NO.
5342

GROUP
1642

FOREIGN PATENT DOCUMENTS

[illegible]

EXAMINER

DATE CONSIDERED